Corrections to design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists (Journal of Medicinal Chemistry (2009) 52, (1416) DOI 10.1021/jm801272c);Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 5, 2009, Pages 1416-1427

  Li, Guo ^a   Aschenbach, Lindsey C ^a   Chen, Jianyang ^a,b   Cassidy, Michael P ^a   Stevens, David L ^a   Gabra, Bichoy H ^a   Selley, Dana E ^a   Dewey, William L ^a   Westkaemper, Richard B ^a   Zhang, Yan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Zhejiang Jingxin Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA(BENZAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(2' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(2' QUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(3' ISOQUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(3' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(3' QUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA[(4' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA(BENZAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(2' NAPHTHALYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(2' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(2' QUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(3' ISOQUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(3' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(3' QUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA[(4' PYRIDYL)ACETAMIDO]MORPHINAN; NALTREXAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN;

EID: 64349119538     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9016224     Document Type: Erratum

References (62)

1. Zimmerman, D. M.; Leander, J. D. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J. Med. Chem. 1990, 33, 895-902.
2. Schmidhammer, H. Opioid Receptor Antagonists. Prog. Med. Chem. 1998, 35, 83-132.
3. Snyder, S. H.; Pasternak, G. W. Historical Review: Opioid Receptors. Trendss Pharmacol. Sci. 2003, 24 (4), 198-205.
4. Fiellin, D. A.; Kleber, H.; Trumble-Hejduk, J. G.; McLellan, A. T.; Kosten, T. R. Consensus statement in office-based treatment of opioid dependence using buprenorphine. J. Subst. Abuse Treat. 2004, 27, 153-159.
5. Gold, M. S.; Dackis, C. A.; Pottash, A. L.; Sternbach, H. H.; Annitto, W. J.; Martin, D.; Dackis, M. P. Naltrexone, opiate addiction, and endorphins. Med. Res. Rev. 1982, 2 (3), 211-246.
6. Gonzalez, J. P.; Brogden, R. N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988, 35, 192-213.
7. Schwyzer, R. ACTH: a short introductory review. Ann. N.Y. Acad. Sci. 1977, 297, 3-26.
8. Portoghese, P. S.; Lipkowski, A. W.; Takemori, A. E. Binaltorphimine and nor-bionaltorphimine, potent and selective kappa opioid receptor antagonists. Life Sci. 1987, 40, 1287-1292.
9. Jones, R. M.; Hjorth, S. A.; Schwartz, T. W.; Portoghese, P. S. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J. Med. Chem. 1998, 41 (25), 4911-4914.
10. Portoghese, P. S.; Sultana, M.; Nagase, H.; Takemori, A. E. Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonist. J. Med. Chem. 1988, 31, 281-282.
11. Schmidhammer, H.; Burkard, W. P.; Eggstin-Aeppli, L.; Smith, C. F. C. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropymethyl)-4,14-dimethoxymorphinana-6-one, a selective mu opioid receptor antagonist. J. Med. Chem. 1989, 32, 418-421.
12. 35S]GTPgammaS binding assays. Eur. J. Pharmacol. 1999, 383 (2), 209-214.
13. Schmidhammer, H.; Jennewein, H. K.; Krassnig, R.; Traynor, J. R.; Patel, D.; Bell, K.; Froschauer, G.; Mattersberger, K.; Jachs-Ewinger, C.; Jura, P.; Fraser, G. L.; Kalinin, V. N. Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J. Med. Chem. 1995, 38 (16), 3071-3077.
14. Schmidhammer, H.; Jennewein, H. K.; Smith, C. F. Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. Arch. Pharm. (Weinheim). 1991, 324 (4), 209-211.
15. Schmidhammer, H.; Smith, C. F.; Erlach, D.; Koch, M.; Krassnig, R.; Schwetz, W.; Wechner, C. Synthesis and biological evaluation of 14-alkoxymorphinans. 3. Extensive study on cyprodime-related compounds. J. Med. Chem. 1990, 33 (4), 1200-1206.
16. Schmidhammer, H.; Smith, C. F.; Erlach, D.; Koch, M.; Krassnig, R.; Schwetz, W.; Wechner, C. Cyprodime analogues: synthesis and pharmacological evaluation. Prog. Clin. Biol. Res. 1989, 328, 37-40.
17. Spetea, M.; Schullner, F.; Moisa, R. C.; Berzetei-Gurske, I. P.; Schraml, B.; Dorfler, C.; Aceto, M. D.; Harris, L. S.; Coop, A.; Schmidhammer, H. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime. J. Med. Chem. 2004, 47 (12), 3242-3247.
18. Lewis, J. W.; Smith, C. F. C.; McCarthy, P. S.; Walter, D.; Kobylecki, R. J.; Myers, M.; Haynes, A. S.; Lewis, C. J.; Waltham, K. New 14-aminomorphinones and codeinones. NIDA Res. Monogr. 1988, 90, 136-143.
19. Portoghese, P. S.; Takemori, A. E. Affinity labels as probes for opioid receptor types and subtypes. NIDA Res. Monogr. 1986, 69, 157-168.
20. Burke, T. F.; Woods, J. H.; Lewis, J. W.; Medzihradsky, F. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J. Pharmacol. Exp. Ther. 1994, 271 (2), 715-721.
21. Eguchi, M. Recent advances in selective opioid receptor agonists and antagonists. Med. Res. Rev. 2004, 24 (2), 182-212.
22. Pelton, J. T.; Kazmierski, W.; Gulya, K.; Yamamura, H. I.; Hruby, V. J. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J. Med. Chem. 1986, 29, 2370-2375.
23. Gulya, K.; Pelton, J. T.; Hruby, V. J.; Yamamura, H. I. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. Life Sci. 1986, 38, 2221-2230.
24. 3H]- [H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. J. Pharmacol. Exp. Ther. 1989, 248 (1), 73-81.
25. Kramer, T. H.; Shook, J. E.; Kazmierski, W.; Ayres, E. A.; Wire, W. S.; Hruby, V. J.; Burks, T. F. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 1989, 249 (2), 544-551.
26. Hruby, V. J.; Toth, G.; Gehrig, C. A.; Kao, L. F.; Knapp, R.; Lui, G. K.; Yamamura, H. I.; Kramer, T. H.; Davis, P.; Burks, T. F. Topographically designed analogues of [D-Pen, D-Pen5]enkephalin. J. Med. Chem. 1991, 34 (6), 1823-1830.
27. (a) Mulder, A. H.; Wardeh, G.; Hogenboom, F.; Kazmierski, W.; Hruby, V. J.; Schoffelmeer, A. N. Cyclic somatostatin analogues as potent antagonists at mu-, but not delta- and kappa-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain. Eur. J. Pharmacol. 1991, 205 (1), 1-6.
28. (b) Abbruscato, T. J.; Thomas, S. A.; Hruby, V. J.; Davis, T. P. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 1997, 280 (1), 402-409.
29. Bonner, G. G.; Davis, P.; Stropova, D.; Edsall, S.; Yamamura, H. I.; Porreca, F.; Hruby, V. J. Opiate aromatic pharmacophore structure- activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays. J. Med. Chem. 2000, 43 (4), 569-580.
30. Okada, T.; Le Trong, I.; Fox, B. A.; Behnke, C. A.; Stenkamp, R. E.; Palczewski, K. X-Ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. J. Struct. Biol. 2000, 130 (1), 73-80.
31. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40 (26), 7761-7772.
32. Salom, D.; Le Trong, I.; Pohl, E.; Ballesteros, J. A.; Stenkamp, R. E.; Palczewski, K.; Lodowski, D. T. Improvements in G protein-coupled receptor purification yield light stable rhodopsin crystals. J. Struct. Biol. 2006, 156 (3), 497-504.
33. Salom, D.; Lodowski, D. T.; Stenkamp, R. E.; Le Trong, I.; Golczak, M.; Jastrzebska, B.; Harris, T.; Ballesteros, J. A.; Palczewski, K. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (44), 16123-16128.
34. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature. 2008, 454, 183-187.
35. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta(2) adrenergic G-protein-coupled receptor. Nature 2007, 450 (7168), 383-387.
36. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Yao, X.-J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR Engineering Yields High-Resolution Structural Insights into 2 Adrenergic Receptor Function. Science, 2007, 318 (5854), 1266-1273.
37. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-Resolution Crystal Structure of an Engineered Human 2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318 (5854), 1258-1265.
38. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V. P.; Chien, E. Y.; Velasquez, J.; Kuhn, P.; Stevens, R. C. A specific cholesterol binding site is established by the 2.8 Å structure of the human beta2-adrenergic receptor. Structure 2008, 16 (6), 897-905.
39. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta(1)-adrenergic G-protein-coupled receptor. Nature 2008, 454 (7203), 486-491.
40. Zhang, Y.; Sham, Y. Y.; Rajamani, R.; Gao, J. L.; Portoghese, P. S. Homology Modeling of the Mu Opioid Receptor Built in a Complete Membrane-Aqueous System. ChemBioChem 2005, 6, 853-859.
41. Metzger, T. G.; Paterlini, M. G.; Ferguson, D. M.; Portoghese, P. S. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J. Med. Chem. 2001, 44, 857-862.
42. Ulens, C.; Baker, L.; Ratka, A.; Waumans, D.; Tytgat, J. Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem. Pharmacol. 2001, 62, 1273-1282.
43. Fowler, C. B.; Pogozheva, I. D.; LeVine, H., III.; Mosberg, H. I. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry 2004, 43, 8700-8710.
44. Xue, J.-C.; Chen, C.; Zhu, J.; Kunapuli, S. P.; de Riel, J. K.; Yu, L.; Liu-Chen, L.-Y. The third extracellular loop of the mu opioid receptor is important for agonist selectivity. J. Biol. Chem. 1995, 270, 12977-12979.
45. Bonner, G.; Meng, F.; Akil, H. Selectivity of mu-opioid receptor determined by interfacial residues near the third extracellular loop. Eur. J. Pharmacol. 2000, 403, 37-44.
46. Zhu, J.; Xue, J.-C.; Law, P.-Y.; Claude, P. A.; Luo, L.-Y.; Yin, J.; Chen, C.; Liu-Chen, L.-Y. The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996, 384, 198-202.
47. Xu, W.; Li, J.; Chen, C.; Huang, P.; Weinstein, H.; Javitch, J. A.; Shi, L.; de Riel, J. K.; Liu-Chen, L. Y. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding- site crevices of mu, delta, and kappa opioid receptors. Biochemistry 2001, 40, 8018-8029.
48. Law, P. Y.; Wong, Y. H.; Loh, H. H. Mutational analysis of the structure and function of opioid receptors. Biopolymers 1999, 51 (6), 440-455.
49. Xu, H.; Lu, Y. F.; Partilla, J. S.; Zheng, Q. X.; Wang, J. B.; Brine, G. A.; Carroll, F. I.; Rice, K. C.; Chen, K. X.; Chi, Z. Q.; Rothman, R. B. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat μ-opioid receptor in binding of μ-selective ligands. Synapse (New York) 1999, 32 (1), 23-28.
50. Griffin, J. F.; Larson, D. L.; Portoghese, P. S. Crystal structures of alpha- and beta-funaltrexamine: conformational requirement of the fumaramate moiety in the irreversible blockage of mu opioid receptors. J. Med. Chem. 1986, 29 (5), 778-783.
51. Sayre, L. M.; Portoghese, P. S. Stereospecific synthesis of the 6α- and 6β-amino derivatives of naltrexone and oxymorphone. J Org. Chem. 1980, 45, 3366-3368.
52. Keen, M. Testing models of agonism for G protein-coupled receptors. Trends Pharmacol. Sci. 1991, 12 (10), 371-374.
53. Selley, D. E.; Sim, L. J.; Xiao, R.; Liu, Q.; Childers, S. R. Mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 1997, 51 (1), 87-96.
54. Selley, D. E.; Liu, Q.; Childers, S. R. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 1998, 285, 496-505.
55. Morgan, D.; Cook, C. D.; Picker, M. J. Sensitivity to the discriminative stimulus and antinociceptive effects of mu opioids: role of strain of rat, stimulus intensity, and intrinsic efficacy at the mu opioid receptor. J. Pharmacol. Exp. Ther. 1999, 289 (2), 965-975.
56. Morgan, D.; Cook, C. D.; Smith, M. A.; Picker, M. J. An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. Anesth. Analg. 1999, 88 (2), 407-413.
57. i values for this mutant. These results indicate that these two leads could recognize an "address" locus with potential hydrogen bonding property in the MOR, which could confer their selectivity for the MOR over the DOR and KOR.
58. Insight II User Guide; MSI: San Diego, October 1995.
59. Coderre, T. J.; Rollman, G. B. Naloxone hyperalgesia and stress-induced analgesia in rats. Life Sci. 1983, 32 (18), 2139-2146.
60. Harris, L. S.; Pierson, A. K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 1964, 143, 141-148.
61. Bliss, C. I. Statistics in Biology; McGraw-Hill: New York, 1967; p 439.
62. Xhaard, H.; Nyronen, T.; Rantanen, V. V.; Ruuskanen, J. O.; Laurila, J.; Salminen, T.; Scheinin, M.; Johnson, M. S. Model structures of α-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. J. Struct. Biol. 2005, 150, 126-143.